Skip to main content

Advertisement

SpringerLink
Log in

Primary Prevention of Cardiovascular Disease with Statins in the Elderly

  • Cardiovascular Disease and Stroke (P Perrone-Filardi and S. Agewall, Section Editors)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Owing to the progressive aging of the population, and the fact that cardiovascular disease (CVD) is the leading cause of death among the elderly, the prevention of CVD in the elderly is becoming increasingly important. Although there is no doubt that statin treatment should be used for reducing CVD risk in the elderly in secondary prevention in the same way as in younger individuals, the evidence that such treatment really prolongs life in elderly subjects in primary prevention is still not so clear. However, it seems that it does reduce CVD morbidity in elderly individuals. Because of limited evidence regarding the benefit of such therapy, particularly in very old subjects (older than 80–85 years), the decision whether to treat or not treat an elderly individual with statins in primary prevention should be based on good clinical judgment and considering the individual subject’s situation regarding comorbidities, polypharmacy, and possible adverse effects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. Merkler M, Reiner Ž. The burden of hyperlipidaemia and diabetes in cardiovascular diseases. Fundam Clin Pharmacol. 2007;21 Suppl 2:1–3.

    Article  CAS  PubMed  Google Scholar 

  2. Moran A, Zhao D, Gu D, Coxson P, Chen CS, Cheng J, et al. The future impact of population growth and aging on coronary heart disease in China: projections from the Coronary Heart Disease Policy Model-China. BMC Public Health. 2008;8:394.

    Article  PubMed Central  PubMed  Google Scholar 

  3. Odden MC, Coxson PG, Moran A, Lightwood JM, Goldman L, Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. Am J Med. 2011;124(9):827–33.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28(19):2375–414.

    Article  PubMed  Google Scholar 

  5. Ducharme N, Radhamma R. Hyperlipidemia in the elderly. Clin Geriatr Med. 2008;24(3):471–87.

    Article  PubMed  Google Scholar 

  6. Lemaitre RN, Furberg CD, Newman AB, Hulley SB, Gordon DJ, Gottdiener JS, et al. Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. Arch Intern Med. 1998;158(16):1761–8.

    Article  CAS  PubMed  Google Scholar 

  7. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in older men with established coronary heart disease. Heart. 2002;88(1):25–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291(15):1864–70.

    Article  CAS  PubMed  Google Scholar 

  9. Gnavi R, Migliardi A, Demaria M, Petrelli A, Caprioglio A, Costa G. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health. 2007;17(5):492–6.

    Article  PubMed  Google Scholar 

  10. Niska R, Han B. Statins for secondary cardiovascular disease prevention for older primary care patients. J Natl Med Assoc. 2009;101(7):705–10.

    PubMed  Google Scholar 

  11. Robinson JG, Booth B. Statin use and lipid levels in older adults: National Health and Nutrition Examination Survey, 2001 to 2006. J Clin Lipidol. 2010;4(6):483–90.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Reiner Ž. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol. 2013;10(8):453–64. This is the most recent and most comprehensive review of the use of statins in the primary prevention of CVD, including in the elderly.

    Article  CAS  PubMed  Google Scholar 

  13. Reiner Ž, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32(14):1769–818. These are the first European guidelines for the management of dyslipidemias containing an important section on the treatment of dyslipidemias in the elderly.

    Article  PubMed  Google Scholar 

  14. Perk J, De Backer G, Gohlke H, Graham I, Reiner Ž, Verschuren M, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33(13):1635–701.

    Article  CAS  PubMed  Google Scholar 

  15. Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. doi:10.1161/01.cir.0000437738.63853.7a. These are the most recent US guidelines on the treatment of hypercholesterolemia, mentioning also the treatment of the elderly.

    PubMed Central  Google Scholar 

  16. Ray KK, Kastelein JJP, Boekholdt SM, Nicholls SJ, Khaw K-T, Ballantyne CM, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults - the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014; doi10.1093/eurheartj/ehu107

  17. Graham I, Cooney MT, Bradley D, Dudina A, Reiner Ž. Dyslipidemias in the prevention of cardiovascular disease: risks and causality. Curr Cardiol Rep. 2012;14(6):709–20.

    Article  PubMed  Google Scholar 

  18. De Backer G, Catapano AL, Chapman J, Graham I, Reiner Ž, Perk J, et al. Guidelines on CVD prevention: confusing or complementary? Atherosclerosis. 2013;226(1):299–300.

    Article  PubMed  Google Scholar 

  19. National Heart, Blood, and Lung Institute. NHLBI, estimate of 10-year risk for CHD. http://www.nhlbi.nih.gov/guidelines/cholesterol/risk_tbl.htm. Accessed February 14, 2014.

  20. Zannad F, Dallongeville J, Macfadyen RJ, Ruilope LM, Wilhelmsen L, De Backer G, et al. Prevention of cardiovascular disease guided by total risk estimations - challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) workshop of the ESC Working Group on Cardiovascular Pharmacology and Drug Therapy. Eur J Prev Cardiol. 2012;19(6):1454–64.

    Article  PubMed Central  PubMed  Google Scholar 

  21. Zannad F, De Backer G, Graham I, Lorenz M, Mancia G, Morrow DA, et al. Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques. Fundam Clin Pharmacol. 2012;26(2):163–74.

    Article  CAS  PubMed  Google Scholar 

  22. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  Google Scholar 

  23. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279(20):1615–22.

    Article  CAS  PubMed  Google Scholar 

  25. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149–58.

    Article  CAS  PubMed  Google Scholar 

  26. Nakaya N, Mizuno K, Ohashi Y, Teramoto T, Yokoyama S, Hirahara K, et al. Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study). Drugs Aging. 2011;28(9):681–92.

    Article  CAS  PubMed  Google Scholar 

  27. Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med. 2002;162(12):1395–400.

    Article  CAS  PubMed  Google Scholar 

  28. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–30.

    Article  CAS  PubMed  Google Scholar 

  29. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152(8):488–96.

    Article  PubMed Central  PubMed  Google Scholar 

  30. Zieman SJ, Ouyang P. Statins for primary prevention in older adults: who is high risk, who is old, and what denotes primary prevention? Ann Intern Med. 2010;152(8):528–30.

    Article  PubMed  Google Scholar 

  31. Savarese G, Gotto Jr AM, Paolillo S, D'Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J Am Coll Cardiol. 2013;62(22):2090–9. This article provides very recent data showing that in elderly subjects at high CVD risk but without established CVD, statins significantly reduce the incidence of myocardial infarction and stroke, but do not significantly prolong survival in the short term.

    Article  CAS  PubMed  Google Scholar 

  32. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011;10(3):373–87.

    Article  CAS  PubMed  Google Scholar 

  33. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109–24.

    Article  CAS  PubMed  Google Scholar 

  34. Mancini GB, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, et al. Can J Cardiol. 2011 Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. Canad. J Cardiol. 2011;27(5):635–62.

    Google Scholar 

  35. Gaist D, Rodríguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology. 2001;12(5):565–9.

    Article  CAS  PubMed  Google Scholar 

  36. Alexander KP, Blazing MA, Rosenson RS, Hazard E, Aronow WS, Smith Jr SC, et al. Management of hyperlipidemia in older adults. J Cardiovasc Pharmacol Ther. 2009;14(1):49–58.

    Article  CAS  PubMed  Google Scholar 

  37. Bhardwaj S, Selvarajah S, Schneider EB. Muscular effects of statins in the elderly female: a review. Clin Interv Aging. 2013;8:47–59.

    CAS  PubMed Central  PubMed  Google Scholar 

  38. Argo CK, Loria P, Caldwell SH, Lonardo A. Statins in liver disease: a molehill, an iceberg, or neither? Hepatology. 2008;48(2):662–9.

    Article  CAS  PubMed  Google Scholar 

  39. Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. 2014;45(1):52–7.

    Article  CAS  PubMed  Google Scholar 

  40. Younoszai Z, Li Z, Stepanova M, Erario M, Cable R, Younossi ZM. Statin use is not associated with liver related mortality. Ann Hepatol. 2013–2014;13(1):84–90.

  41. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115(1):27–33.

    Article  CAS  PubMed  Google Scholar 

  42. Hunt D, Young P, Simes J, Hague W, Mann S, Owensby D, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med. 2001;134(10):931–40.

    Article  CAS  PubMed  Google Scholar 

  43. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477–86.

    Article  CAS  PubMed  Google Scholar 

  44. Cholesterol Treatment Trialists’ (CTT) Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS ONE. 2012;7(1):e29849.

    Article  CAS  PubMed  Google Scholar 

  45. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375(9716):735–42.

    Article  CAS  PubMed  Google Scholar 

  46. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–64.

    Article  CAS  PubMed  Google Scholar 

  47. Wang KL, Liu CJ, Chao TF, Huang CM, Wu CH, Chen SJ, et al. Statins, risk of diabetes, and implications on outcomes in the general population. J Am Coll Cardiol. 2012;60(14):1231–8.

    Article  CAS  PubMed  Google Scholar 

  48. Ma T, Tien L, Fang C-L, Liou YS, Jong GP. Statins and new-onset diabetes: a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977–83.

    Article  CAS  PubMed  Google Scholar 

  49. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172(2):144–52.

    Article  PubMed  Google Scholar 

  50. Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357–62.

    Article  CAS  PubMed  Google Scholar 

  51. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380(9841):565–71.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews KA, et al. Effects of lovastatin on cognitive function and psychological well-being. Am J Med. 2000;108(7):538–46.

    Article  CAS  PubMed  Google Scholar 

  54. Jakovljević M, Reiner Z, Miličić D. Mental disorders, treatment response, mortality and serum cholesterol: a new holistic look at old data. Psychiatr Danub. 2007;19(4):270–81.

    PubMed  Google Scholar 

  55. Leuschen J, Mortensen EM, Frei CR, Mansi EA, Panday V, Mansi I. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427–34.

    Article  PubMed  Google Scholar 

  56. Sheppard JP, Singh S, Fletcher K, et al. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ. 2012;345:e4535.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  57. Upmeier E, Korhonen MJ, Helin-Salmivaara A, Huupponen R. Statin use among older Finns stratified according to cardiovascular risk. Eur J Clin Pharmacol. 2013;69(2):261–7.

    Article  CAS  PubMed  Google Scholar 

  58. Chokshi NP, Messerli FH, Sutin D, Supariwala AA, Shah NR. Appropriateness of statins in patients aged ≥80 years and comparison to other age groups. Am J Cardiol. 2012;110(10):1477–81.

    Article  CAS  PubMed  Google Scholar 

  59. Dornbrook-Lavender KA, Roth MT, Pieper JA. Secondary prevention of coronary heart disease in the elderly. Ann Pharmacother. 2003;37(12):1867–76.

    Article  PubMed  Google Scholar 

  60. Mann DM, Woodward M, Muntner P, Falzon L, Kronish I. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44(9):1410–21.

    Article  PubMed Central  PubMed  Google Scholar 

  61. Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol. 2010;4(6):462–71.

    Article  PubMed  Google Scholar 

  62. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Public perceptions of cardiovascular risk factors in Croatia: the PERCRO survey. Prev Med. 2010;51(6):494–6.

    Article  PubMed  Google Scholar 

  63. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis. 2010;213(2):598–603.

    Article  CAS  PubMed  Google Scholar 

  64. Reiner Ž, Sonicki Z, Tedeschi-Reiner E. The perception and knowledge of cardiovascular risk factors among medical students. Croat Med J. 2012;53(3):278–84.

    Article  PubMed Central  PubMed  Google Scholar 

  65. Reiner Ž, De Bacquer D, Kotseva K, Prugger C, De Backer G, Wood D, et al. Treatment potential for dyslipidaemia management in patients with coronary heart disease across Europe: findings from the EUROASPIRE III survey. Atherosclerosis. 2013;231(2):300–7.

    Article  CAS  PubMed  Google Scholar 

  66. Reiner Ž, Tedeschi-Reiner E. Prevalence and types of persistent dyslipidemia in patients treated with statins. Croat Med J. 2013;54(4):339–45.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Željko Reiner has received personal fees from Abbott, AstraZeneca, and Merck, and grants and personal fees from Sanofi.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the author.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia

    Željko Reiner

Authors
  1. Željko Reiner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Željko Reiner.

Additional information

This article is part of the Topical Collection on Cardiovascular Disease and Stroke

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Reiner, Ž. Primary Prevention of Cardiovascular Disease with Statins in the Elderly. Curr Atheroscler Rep 16, 420 (2014). https://doi.org/10.1007/s11883-014-0420-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-014-0420-6

Keywords

Search

Navigation